BioLineRx
BLRX | NASDAQ
$1.19
-$0.11 (-8.46%)
At close: Nov 16, 2026, 3:59 PM ET
$1.16
-$0.03 (-2.39%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-8.46%
(1D)No price chart data available for 1D timeframe.
Rating
36.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #619/1021 (Top 61%)
Key Statistics
Market Data
Market Cap $5.92M
1D Range
1.14 1.33
52W Range
1.14 3.78
Valuation (TTM)
PE -0.66
PB 0.43
EV/EBITDA -0.10
Valuation (NTM)
Forward PE N/A
Forward PEG -0.00
Price Target $0.00
Cash Flow
FCF Yield -184.0%
SBC Adj. FCF Yield -187.0%
SBC Impact -1.6%
Margins
Gross Margin 69.8%
Operating Margin -876.3%
FCF Margin -779.6%
Growth (CAGR)
Revenue 3Y | 5Y -65.8% |
28.1%
Dil EPS 3Y | 5Y 106.9% |
41.6%
FCF 3Y | 5Y 46.9% |
14.7%
Returns
ROA -24.2%
ROE -47.2%
ROIC -50.1%
Financial Health
Net Cash
$6.1M
Current Ratio 1.20
Interest Coverage -11.65
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational pr...
Sector Healthcare
Industry Biotechnology
Employees 22
IPO Date Jul 27, 2011
Website www.biolinerx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove BLRX